

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAREPTA THERAPEUTICS, INC.,

Petitioner

v.

Genzyme Corporation,

Patent Owner

U.S. Patent No. 9,051,542

“Compositions and Methods to Prevent AAV Vector Aggregation”

IPR2025-01194

PETITIONER’S *SOTERA* STIPULATION

Petitioner hereby stipulates that, if the Board institutes *inter partes* review in this proceeding, IPR2025-01194, Petitioner will not pursue in the parallel litigation, *Genzyme Corp. v. Sarepta Therapeutics, Inc. et al.*, C.A. No. 24-cv-00882-RGA (D. Del.), (1) the same grounds in the Petition (Paper 1), or (2) any grounds of invalidity arising under U.S.C. § 102 or § 103 involving patent or printed publication prior art that could have reasonably been raised before the Board with respect to U.S. Patent No. 9,051,542.

Date: July 30, 2025

/s/ Robert B. Wilson

Robert B. Wilson
Registration No. 45,227
Quinn Emanuel Urquhart & Sullivan,
LLP
295 Fifth Avenue, 9th Floor
New York, New York 10016
Tel.: 212-849-7000
Fax: 212-849-7100

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6, I hereby certify that on July 30, 2025 the foregoing document was served via email on the following counsel of record:

Amanda K. Antons
amanda.antons@dechert.com

Katherine A. Helm
khelm@dechert.com

Blaine M. Hackman
blaine.hackman@dechert.com

/s/ Robert B. Wilson

Robert B. Wilson
Registration No. 45,227
Quinn Emanuel Urquhart & Sullivan,
LLP
295 Fifth Avenue, 9th Floor
New York, New York 10016
Tel.: 212-849-7000
Fax: 212-849-7100